SLC8B1 Antibody

What is SLC8B1 and why is it important in research?

SLC8B1 (solute carrier family 8 member B1) is a mitochondrial Na⁺/Ca²⁺/Li⁺ exchanger protein that regulates mitochondrial calcium efflux. In humans, the canonical protein has 584 amino acid residues with a molecular mass of approximately 64.2 kDa . SLC8B1 is critically important in research because it represents the primary mechanism for mitochondrial calcium extrusion in excitable cells . It belongs to the Ca²⁺:cation antiporter (CaCA) protein family and plays essential roles in:

• Regulating mitochondrial calcium levels

• Maintaining cellular calcium homeostasis

• Influencing carbohydrate metabolism

• Controlling mitochondrial redox state

• Regulating cell death pathways

Research has demonstrated that SLC8B1 dysfunction is implicated in heart failure, neurodegenerative disorders, and various cancer types, making it a significant target for investigation .

How do SLC8B1 antibodies differ from other mitochondrial protein antibodies?

SLC8B1 antibodies are specifically designed to detect the mitochondrial Na⁺/Ca²⁺ exchanger, which has unique structural characteristics:

When selecting antibodies, researchers should verify that the epitope is accessible in their experimental conditions, as the complex transmembrane structure can present challenges for antibody binding . Unlike many mitochondrial proteins that may have cytosolic domains, SLC8B1's topology requires careful consideration of membrane permeabilization techniques during immunostaining procedures.

Which detection methods are most effective with SLC8B1 antibodies?

Based on validation data from multiple sources, SLC8B1 antibodies have been successfully employed in various applications with differing effectiveness:

Western blot represents the most widely validated application for SLC8B1 antibodies . When performing immunohistochemistry, researchers should be aware that SLC8B1 expression varies significantly between tissues, with notable expression in lymph nodes and pancreas . For optimal results in any application, antibody validation using both positive controls and NCLX knockout samples is strongly recommended .

How should SLC8B1 antibodies be validated before experimental use?

Proper validation of SLC8B1 antibodies is critical for experimental reliability. A comprehensive validation protocol should include:

• Positive control tissues/cells: Lymph nodes, pancreas, and cardiac tissue express relatively high levels of SLC8B1 and serve as good positive controls .

• Genetic controls: Validation using CRISPR/Cas9-generated NCLX knockout cell lines or tissues. Researchers have successfully created NCLX knockout models by:

  • Deleting nucleotides 120513241-120513253 on chromosome 13 (mouse model)

  • Using shRNA knockdown (60% reduction in SLC8B1 mRNA levels is achievable)

• Peptide competition assays: Pre-incubating the antibody with the immunizing peptide should abolish specific staining .

• Multiple antibody comparison: Using different antibodies targeting distinct epitopes of SLC8B1 to confirm specificity .

• Cross-reactivity assessment: Testing in multiple species if cross-reactivity is claimed (human, mouse, rat are commonly validated) .

A systematic validation approach revealed that antibodies recognizing the middle region of SLC8B1 often demonstrate higher specificity in Western blot applications .

What are the optimal sample preparation protocols for detecting SLC8B1?

Effective detection of SLC8B1 requires careful consideration of its mitochondrial localization:

For Western Blot:

• Use mitochondrial isolation protocols to enrich for SLC8B1 content

• Solubilize samples in buffers containing mild detergents (0.5% Triton X-100 or CHAPS)

• Include protease inhibitors to prevent degradation

• Load 20-30 μg of mitochondrial protein per lane

• Run on 10-12% SDS-PAGE gels

For Immunohistochemistry:

• Formalin-fixed paraffin-embedded (FFPE) tissues yield best results

• Antigen retrieval in citrate buffer (pH 6.0) improves signal

• Dilutions between 1:25-1:100 are typically effective

• Counterstain with mitochondrial markers to confirm localization

For Immunocytochemistry:

• Fixation with 4% paraformaldehyde

• Permeabilization with 0.2% Triton X-100

• Co-staining with MitoTracker or other mitochondrial markers

• Confocal microscopy for precise subcellular localization

How does SLC8B1 expression vary across tissues and disease states?

Understanding SLC8B1 expression patterns is crucial for experimental design and interpretation:

Normal Tissue Expression:

• Highest expression: Lymph nodes, pancreas, and cardiac tissue

• Moderate expression: Liver, kidney, and brain

• Expression in multiple species: Human, mouse, rat, bovine, zebrafish, and chimpanzee

Disease-Associated Expression Changes:

• Colorectal cancer: Significantly downregulated in both colon and rectal adenocarcinomas compared to adjacent normal tissue

• Cancer progression: Greater reduction in late-stage (III and IV) compared to early-stage (I and II) colorectal tumors

• Genetic associations: Low NCLX expression associated with TP53 mutations and wild-type BRAF tumors

This expression pattern suggests that SLC8B1 downregulation correlates with disease progression in colorectal cancer, although the functional consequences appear complex .

How can researchers address contradictory findings regarding SLC8B1 in cancer?

Research has revealed an intriguing dichotomy in SLC8B1's role in cancer development:

Observational data in human samples:

• SLC8B1 expression is significantly downregulated in colorectal tumors

• Lower expression correlates with advanced cancer stages

• Associated with TP53 mutations

Functional studies in mouse models:

• Global NCLX (SLC8B1) knockout mice developed approximately 50% fewer colorectal tumors than control mice in an AOM-DSS model

• Tumors in knockout mice were markedly smaller than in control mice

• NCLX knockout reduced dysplasia in colon tissues

Cellular studies:

• NCLX knockout in CRC cell lines (HCT116, DLD1) reduced proliferation

• Increased apoptosis (cleaved caspase-3) observed in NCLX knockout cells

To address these seemingly contradictory findings, researchers should:

• Consider tissue-specific effects by using conditional knockout models rather than global knockouts

• Examine mitochondrial calcium dynamics in different stages of tumor development

• Investigate compensatory mechanisms that may emerge in knockout models

• Study SLC8B1's role in specific cancer-associated signaling pathways

• Combine observational studies with functional validations in the same experimental system

This complexity highlights the need for nuanced experimental designs when investigating SLC8B1's role in cancer biology.

What controls should be included when studying SLC8B1 using antibodies?

To ensure experimental rigor when studying SLC8B1, include these essential controls:

Positive Controls:

• Cell lines with confirmed high SLC8B1 expression (cardiomyocytes, pancreatic cells)

• Recombinant SLC8B1 protein for Western blot standardization

• Tissues with known expression (lymph nodes, pancreas)

Negative Controls:

• CRISPR/Cas9-generated SLC8B1 knockout cells

• shRNA knockdown cells (verified by qPCR)

• Primary antibody omission controls

• Isotype controls matching the primary antibody's host species

Validation Controls:

• Peptide competition assays to confirm specificity

• Multiple antibodies targeting different epitopes

• mRNA expression correlation (qPCR)

• Mitochondrial markers to confirm localization

Experimental Controls:

• When manipulating SLC8B1 expression, assess mitochondrial calcium levels

• Monitor mitochondrial morphology and function (membrane potential, ROS production)

• Include controls for potential compensatory mechanisms (other Na⁺/Ca²⁺ exchangers)

How can researchers effectively study SLC8B1's role in mitochondrial calcium regulation?

Investigating SLC8B1's function in mitochondrial calcium regulation requires sophisticated methodological approaches:

Genetic Manipulation Strategies:

• CRISPR/Cas9 knockout: 13 nucleotide deletion in exon 1 (positions 120513241-120513253) creating frameshift mutation

• Conditional knockout using Cre-loxP system (e.g., αMHC-MerCreMer for cardiomyocyte-specific deletion)

• Tetracycline-inducible overexpression systems for temporal control

• Site-directed mutagenesis of key residues in ion-binding domains

Calcium Imaging Techniques:

• Mitochondria-targeted calcium indicators (mt-GCaMP, Rhod-2)

• Simultaneous measurement of cytosolic and mitochondrial calcium

• Real-time imaging during physiological stimulation

• Calcium retention capacity assays in isolated mitochondria

Functional Assessments:

• Mitochondrial swelling assays to detect MPTP opening

• ROS measurements using mitochondria-targeted probes

• Membrane potential assessment with TMRM or JC-1

• Oxygen consumption rate measurements

• NAD(P)H autofluorescence to assess redox state

Research has shown that tamoxifen-induced deletion of SLC8B1 in adult mouse hearts causes:

• Mitochondrial calcium overload

• Increased generation of superoxide

• MPTP opening and mitochondrial swelling

• Necrotic cell death and heart failure

These findings highlight the critical role of SLC8B1 in maintaining mitochondrial calcium homeostasis and cellular viability.

What are the most effective approaches for studying SLC8B1 in disease models?

When investigating SLC8B1 in disease contexts, researchers should consider these methodological approaches:

Cardiac Disease Models:

• Tamoxifen-inducible cardiomyocyte-specific deletion using αMHC-MerCreMer

• NCLX overexpression using conditional transgenesis (αMHC-tTA system)

• Ischemia-reperfusion models to assess cardioprotection

• Assessment of cardiac function via echocardiography

• Evans blue dye exclusion technique to detect necrosis

Cancer Models:

• AOM-DSS colitis-associated colorectal cancer model

• Xenograft models with NCLX knockout cancer cells

• Colony formation assays to assess proliferation capacity

• CCK8 assays for cell viability measurements

• Cleaved caspase-3 immunofluorescence for apoptosis detection

Analytical Approaches:

• Gene expression analysis in TCGA datasets

• Correlation with clinical parameters and survival outcomes

• Assessment of microsatellite instability status

• Tumor mutation burden analysis

• Protein-protein interaction network analysis

A comprehensive experimental design should integrate multiple levels of analysis, from molecular mechanisms to physiological outcomes, to fully understand SLC8B1's role in disease pathogenesis.

What methodologies are available for investigating SLC8B1 interactions with other proteins?

Understanding SLC8B1's interactome requires specialized techniques:

Co-immunoprecipitation Strategies:

• Antibody selection is critical; use validated antibodies against distinct epitopes

• Mild detergent conditions to preserve membrane protein interactions

• Crosslinking approaches for transient interactions

• Reciprocal co-IP to confirm interactions

Proximity Labeling Techniques:

• BioID or APEX2 fusion proteins to identify proximal proteins

• TurboID for rapid labeling of neighboring proteins

• Mitochondria-targeted constructs to ensure correct localization

Fluorescence-Based Interaction Studies:

• FRET (Förster Resonance Energy Transfer) for direct interaction assessment

• Split-GFP complementation to visualize protein interactions

• FLIM (Fluorescence Lifetime Imaging Microscopy) for quantitative interaction mapping

Structural Biology Approaches:

• Cryo-EM to resolve the structure of SLC8B1 and its complexes

• Hydrogen-deuterium exchange mass spectrometry to map interaction interfaces

• Computational modeling based on the 13 transmembrane domain structure

Research using STRING database and GeneMANIA analyses has identified potential functional partners of SLC8B1, which may include other calcium transporters, mitochondrial proteins, and signaling molecules . Investigating these interactions can provide insights into the broader functional network in which SLC8B1 operates.

How should researchers interpret contradictory results in SLC8B1 functional studies?

The literature on SLC8B1 contains several apparent contradictions that require careful interpretation:

Dichotomy in Cancer Studies:

• Clinical observation: Reduced SLC8B1 expression correlates with advanced cancer stages

• Functional finding: SLC8B1 knockout reduces tumor growth in experimental models

Possible Explanations:

• Context-dependent functions: SLC8B1 may have different roles depending on:

  • Cancer type and stage

  • Genetic background (TP53 status, BRAF mutations)

  • Microenvironmental conditions

• Compensatory mechanisms: Acute versus chronic loss of SLC8B1 may trigger different adaptive responses

• Dual functions in calcium regulation:

  • Protective role: Preventing calcium overload and cell death

  • Permissive role: Supporting calcium-dependent proliferation pathways

• Methodological differences:

  • Global versus tissue-specific knockout models

  • In vitro versus in vivo studies

  • Transient versus stable gene manipulation

When encountering contradictory results, researchers should:

• Validate findings using multiple experimental approaches

• Consider temporal aspects of SLC8B1 function

• Examine cell-type specific effects

• Assess potential compensatory mechanisms

What statistical considerations are important when analyzing SLC8B1 expression data?

When analyzing SLC8B1 expression in clinical samples or experimental models, consider these statistical approaches:

For Clinical Data Analysis:

• Use paired analysis when comparing tumor vs. adjacent normal tissue

• Stratify by cancer stage, genetic alterations (TP53, BRAF status)

• Apply appropriate multiple testing corrections

• Consider batch effects in multi-center studies

• Correlate with survival using Kaplan-Meier analysis and Cox regression

For Experimental Data:

• Power analysis to determine adequate sample size

• Appropriate controls for each experimental condition

• Normalization to mitochondrial content when analyzing expression

• Statistical tests appropriate for data distribution

• Proper representation of biological and technical replicates

Analysis of SLC8B1 in TCGA Data:
Research has employed these analytical approaches for SLC8B1 in colorectal cancer:

• Comparison between tumor and normal tissues using paired analysis

• Stratification by cancer stage, age groups, histological subtypes

• Assessment of associations with tumor mutation burden

• Correlation with microsatellite instability status

• Integration with clinical outcome data